Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alisertib
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
Alisertib in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2014-0497, NCI-2014-02568, X14024, NCT02293005
Combining MLN8237 with Nab-Paclitaxel in Patients with Advanced Solid Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201210123, NCI-2012-01611, NCT01677559
Alisertib, Bortezomib, and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S12-02028, NCI-2012-01712, CDR0000740877, P9086, 9086, NCT01695941
Alisertib and Romidepsin in Treating Patients with Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0602, NCI-2013-01272, TX035, 9342, NCT01897012
Irinotecan Hydrochloride and Alisertib in Treating Patients with Advanced Solid Tumors or Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#234, NCI-2013-01387, X14013, NCT01923337
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#240, NCI-2013-01388, NCT01924260
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14019, NCI-2014-01843, U1111-1155-6072, NCT02214147
Alisertib and Fulvestrant in Treating Patients with Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1231, NCI-2014-01726, NCT02219789
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C28002, NCI-2015-01108, 2014-003340-12, U1111-1159-5831, NCT02327169
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C032-6001 (MLN1117-1003), NCI-2015-02103, 2015-001032-38, MLN1117-1003, REec-2016-2039, U1111-1166-8653, UTN, NCT02551055
Alisertib in Treating Patients with Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 15H10, NCI-2015-01219, STU00200682, NCT02530619
Start Over